Ieramilimab

Drug Overview

Ieramilimab, also known by its development code LAG525, is an investigational humanized Immunotherapy monoclonal antibody developed by Novartis Pharmaceuticals. It belongs to the rapidly advancing class of immune checkpoint inhibitors — medicines that release the immune system’s natural brakes so it can mount a stronger attack against cancer. Specifically, ieramilimab targets LAG-3 (Lymphocyte Activation Gene-3, also called CD223) — the third major immune checkpoint target after PD-1 and CTLA-4, and one of the most actively investigated in oncology today.

LAG-3 is an inhibitory receptor mainly expressed on T cells, regulatory T cells, and dendritic cells, and it contributes to immune suppression within the tumor microenvironment. Ieramilimab is designed to lift this suppression, making it a precision next-generation Immunotherapy agent.

Key facts at a glance:

• Generic Name: Ieramilimab (LAG525)
• US Brand Name: None assigned — currently investigational
• Drug Class: Anti-LAG-3 Monoclonal Antibody / Immune Checkpoint Inhibitor / Immunotherapy
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: Not FDA-approved. Ieramilimab has completed phase I and phase II clinical trials. Its global highest R&D status is phase 2, with development primarily studied in combination with the anti-PD-1 antibody spartalizumab across multiple solid tumor types.

What Is It and How Does It Work? (Mechanism of Action)

To understand ieramilimab, it helps to know how cancer escapes immune destruction. The immune system deploys T-cells to identify and kill cancer cells. However, inside the tumor microenvironment, cancer cells activate inhibitory proteins on T-cells — essentially “exhausting” them and switching off their cancer-killing function. LAG-3 is one of the most important of these inhibitory checkpoints.

Ieramilimab dismantles this suppression through three molecular steps:

Blocking LAG-3 Ligand Interactions: Ieramilimab primarily blocks the interactions between the D1 domain of LAG-3 and both FGL-1 (IC50, 0.1 nmol/L) and pMHCII (nanomolar affinity). FGL-1 (Fibrinogen-like protein 1) and peptide-MHC class II (pMHCII) are the two main ligands that activate LAG-3’s suppressive function. By blocking both simultaneously, ieramilimab cuts off the two primary pathways through which LAG-3 shuts down T-cell activity.

Restoring T-Cell Function: With LAG-3 blocked, exhausted T-cells regain their capacity to proliferate, produce inflammatory cytokines, and directly kill tumor cells. This is particularly important in tumors where both LAG-3 and PD-1 are co-expressed — a combination associated with the deepest T-cell exhaustion and poorest clinical outcomes.

Synergy with PD-1 Blockade: LAG-3 and PD-1 use distinct but complementary suppression pathways. Ieramilimab has shown considerable potential in restoring exhausted T-cell functionality and boosting antitumor immune responses, and combining it with anti-PD-1 therapy produces greater immune reactivation than either agent alone — the scientific rationale for the ieramilimab plus spartalizumab combination strategy.

FDA Approved Clinical Indications

Oncological Uses (Under Clinical Investigation — Not FDA-Approved):

• Advanced solid malignancies including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), mesothelioma, and triple-negative breast cancer (TNBC) — studied in combination with spartalizumab in the phase II program
• Advanced hematological malignancies — studied in the phase II trial NCT02460224 across multiple tumor types

Non-Oncological Uses:

• There are currently no non-oncological indications under formal clinical investigation for ieramilimab.

Dosage and Administration Protocols

Patients received ieramilimab (400 mg) followed by spartalizumab (300 mg) every 3 weeks in the phase II combination program. Ieramilimab is administered as an IV infusion at a certified oncology treatment center.

Clinical Efficacy and Research Results

Ieramilimab’s clinical evidence spans a comprehensive phase I/II program across multiple solid tumor types. In the foundational phase I/II study (NCT02460224), ieramilimab demonstrated acceptable tolerability as monotherapy and in combination with spartalizumab, establishing the recommended phase II doses used in subsequent expansion cohorts.

In the phase II combination study published in OncoImmunology in December 2023, eligible patients with NSCLC, melanoma, RCC, mesothelioma, and TNBC were grouped depending on prior anti-PD-1/L1 therapy. Patients received ieramilimab (400 mg) followed by spartalizumab (300 mg) every 3 weeks. In previously treated NSCLC patients naïve to prior anti-PD-1/L1 therapy, the ORR was 15% (90%-CI 4.2–34.4). In the anti-PD-1/L1-naïve melanoma cohort, where 55% of patients had refractory disease after 1–2 prior regimens, the ORR was comparable to other LAG-3/PD-1 combinations in pretreated settings. In the anti-PD-1/L1-pretreated melanoma cohort, the ORR was 9.1% in the ieramilimab study compared to 11.5% for relatlimab/nivolumab and 13.3% for fianlimab/cemiplimab, suggesting no clear differentiation between different LAG-3 inhibitor combinations in this specific pretreated setting.

Across the broader LAG-3 inhibitor class, clinical trials with LAG-3 inhibitors combined with anti-PD-1, especially when combined with nivolumab, have shown promising clinical outcomes in melanoma patients, significantly improving progression-free survival rates relative to monotherapy and representing a pivotal advancement in dual checkpoint blockade strategies.

Safety Profile and Side Effects

Black Box Warning: There is no FDA Black Box Warning for ieramilimab, as it is not FDA-approved. Ieramilimab was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study.

Common Side Effects (>10%):

• Fatigue — most frequently reported across combination cohorts; generally grade 1–2 and manageable with supportive care
• Nausea — mild and transient; typically resolves without intervention
• Pruritus (Skin Itching) — consistent with other immune checkpoint inhibitor combinations; managed with topical antihistamines or low-potency corticosteroids
• Infusion-Related Reactions — mild flushing, chills, or low-grade fever during administration; pre-medication with antihistamines reduces incidence

Serious Adverse Events:

• Immune-Mediated Adverse Events: As with all checkpoint inhibitors, ieramilimab can cause inflammation in healthy organs including the lungs (pneumonitis), liver (hepatitis), colon (colitis), and endocrine glands (thyroiditis, adrenal insufficiency); prompt corticosteroid treatment is essential
• Grade 3/4 Treatment-Related Events: Occurred at low rates consistent with the class profile; no unexpected toxicity signals have been identified that are uniquely attributable to LAG-3 blockade versus PD-1 blockade
• Embryo-Fetal Toxicity: Theoretical risk based on immune modulation mechanism; effective contraception is mandatory for all patients of reproductive potential during treatment

Management Strategies:

• For immune-mediated pneumonitis: hold ieramilimab; initiate systemic corticosteroids at 1–2 mg/kg/day prednisone equivalent; permanently discontinue for grade 3 or higher
• For infusion reactions: reduce infusion rate; pre-medicate with diphenhydramine and acetaminophen before subsequent infusions
• For immune-mediated colitis: hold or permanently discontinue based on severity; corticosteroids are first-line management

Research Areas

Ieramilimab occupies an important position in the broader evolution of LAG-3 checkpoint immunotherapy. The approvals of monoclonal antibodies targeting LAG-3 and novel bispecific antibodies targeting immune checkpoints may indicate the next wave of ICI agent development in cancer immunotherapy. While the first FDA-approved LAG-3 inhibitor — relatlimab in combination with nivolumab — has validated the LAG-3 target in melanoma, research into ieramilimab is now focusing on identifying biomarker-selected patient populations most likely to benefit from LAG-3/PD-1 dual blockade. Scientists are exploring LAG-3 expression levels, tumor mutational burden, and T-cell infiltration profiles as predictive biomarkers. Additionally, triple combination strategies pairing ieramilimab with anti-PD-1 and chemotherapy are under preclinical and early clinical investigation in immunologically “cold” tumors such as pancreatic cancer and microsatellite-stable colorectal cancer.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• Complete blood count (CBC) with differential
• Comprehensive metabolic panel including liver function tests (LFTs) and kidney function
• Thyroid function tests (TSH, free T4) — baseline and every 6 weeks during treatment
• LAG-3 expression profiling of tumor tissue where available — emerging predictive biomarker
• Pregnancy test for all women of childbearing age

Precautions During Treatment:

• Monitor thyroid, liver, and pulmonary function throughout the treatment course
• All immune-mediated adverse events must be graded and managed per established checkpoint inhibitor toxicity guidelines
• Ieramilimab is accessible only through participation in an approved clinical trial

Do’s and Don’ts:

• DO inform your entire care team — including primary care physicians, dentists, and emergency providers — that you are receiving immune checkpoint therapy
• DO report any new shortness of breath, persistent diarrhea, or yellowing of the skin immediately
• DO attend all scheduled infusion appointments and laboratory monitoring visits
• DON’T receive live vaccines during treatment or for at least 3 months after the last dose
• DON’T take ieramilimab outside of an approved and supervised clinical trial
• DON’T become pregnant during treatment — immune checkpoint modulation carries a theoretical fetal harm risk

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Ieramilimab (LAG525) is an investigational drug that is not approved by the US Food and Drug Administration (FDA) or any major regulatory authority for routine clinical use. It is currently available only through participation in approved clinical trials. All treatment decisions must be made in consultation with a qualified oncologist or licensed healthcare professional with full knowledge of the patient’s complete medical history. This content does not replace official investigational protocol documentation or professional medical judgment.